Please assess the completion status of the following clinical trial:

Trial Title: Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-50 years~* Men or women~* Vision corrected to at least 20-40~* No tobacco use~* Education of ≥12 years (No GED)~Exclusion Criteria:~* History of major psychiatric illness defined as major depressive disorder, bipolar disorder, post traumatic stress disorder, panic disorder, schizoaffective disorder, schizophrenia or eating disorders~* History of drug or alcohol abuse or dependence~* History of neurological disorders including seizures, brain surgery, multiple sclerosis, Parkinson's disease~* Taking central nervous system (CNS) acting medications (e.g. antidepressants, hypnotics)~* History of allergic reaction or medical contraindication to phenytoin or hydrocortisone therapy~* Metal implants, claustrophobia or other contraindications to MRI~* Significant medical conditions (e.g. myocardial infarction, diabetes)~* Pregnant or nursing women~* Prisoners~* History of mental retardation, special education classes, dementia or other severe cognitive disorders~* Baseline Hamilton Rating Scale for Depression Score \> 7~* History of a suicide attempt~* History of systemic corticosteroid use or current inhaled corticosteroid use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Four Treatments Per Participant (Type: EXPERIMENTAL): This study has one arm due to a crossover design. All 17 subjects received 4 treatments: placebo then placebo, phenytoin then placebo, placebo then hydrocortisone, and phenytoin then hydrocortisone. Each treatment was randomly assigned and had a unique sequence out of 24 possible sequences.

Based on this trial design, predict the completion outcome and termination type (if applicable).